PubMed:32338224 / 7252-7470
Annnotations
LitCovid-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T232 | 59-67 | SP_7 | denotes | COVID-19 |
T233 | 124-128 | PR:000001251 | denotes | AT1R |
T234 | 155-163 | SP_7 | denotes | COVID-19 |
T235 | 199-203 | PR:000001251 | denotes | AT1R |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T46 | 59-67 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T47 | 155-163 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
PubMed_ArguminSci
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T44 | 0-218 | DRI_Background | denotes | Then, Gurwitz suggests to evaluate severity of symptoms in COVID-19 infected patients under previous chronic treatment with AT1R blockers in comparison to COVID-19 infected patients who did not take AT1R blockers [40]. |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T44 | 0-218 | Sentence | denotes | Then, Gurwitz suggests to evaluate severity of symptoms in COVID-19 infected patients under previous chronic treatment with AT1R blockers in comparison to COVID-19 infected patients who did not take AT1R blockers [40]. |